AstraZeneca PLC (AZN)vsKiora Pharmaceuticals Inc (KPRX)
AZN
AstraZeneca PLC
$161.42
+0.88%
HEALTHCARE · Cap: $263.09B
KPRX
Kiora Pharmaceuticals Inc
$2.64
+3.13%
HEALTHCARE · Cap: $11.30M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
KPRX
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.9%
Fair Value
$196.93
Current Price
$161.42
$35.51 discount
Intrinsic value data unavailable for KPRX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bull Case : KPRX
The strongest argument for KPRX centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : KPRX
The primary concerns for KPRX are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while KPRX is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 37/100), backed by strong 17.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Kiora Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative disorders. The company boasts a diverse pipeline of drug candidates aimed at addressing significant unmet medical needs, underpinned by its expertise in drug formulation and delivery. With a strong commitment to enhancing patient outcomes and a solid research framework, Kiora's strategic partnerships and clinical advancements underscore its potential within the biopharmaceutical sector, offering an attractive investment prospect for institutional investors looking to capitalize on the next generation of therapeutics.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?